Beryl Drugs Limited has scheduled its 33rd Annual General Meeting for Tuesday, September 29, 2026. The meeting will take place at Kanchan Palace Community Hall in Indore to transact business outlined in the notice dispatched on September 3, 2026.

The company will close its register of members and share transfer books from September 23 to September 29, 2026, inclusive. This closure determines shareholder eligibility for voting and dividend entitlements.

E-Voting Details

Shareholders holding shares as of the cut-off date of September 22, 2026, may cast their votes electronically. The remote e-voting window opens on September 26, 2026, at 9:00 am and closes on September 28, 2026, at 5:00 pm. The Central Depository Services Limited (CDSL) will disable the e-voting module after this period.

The results of the e-voting, along with the Scrutinizer's Report, will be announced on or after the AGM and posted on the company's website. The Annual Report for the financial year ended March 31, 2026, is available alongside the notice on the company's digital platforms.

Beryl Drugs reported a net profit of ₹42.48 lakh for FY26, down from ₹56.75 lakh in the previous fiscal year. The decline was driven by lower revenue and a temporary regulatory shutdown of its Blow Fill Seal (BFS) manufacturing section.

The company's total revenue for the year ended March 31, 2026, stood at ₹1,931.02 lakh, compared to ₹2,255.48 lakh in FY25. Revenue from operations specifically dropped to ₹1,882.02 lakh from ₹2,114.62 lakh. The Board of Directors has not recommended any dividend for the year.

Financial Performance

The company faced operational headwinds after the Office of the Controller, Food and Drugs Administration, Madhya Pradesh, directed it to stop manufacturing activities in the BFS section effective January 20, 2025. Production was suspended from February 2025 until the order was revoked on November 28, 2025, following compliance measures.

Other income declined significantly to ₹49.00 lakh from ₹140.86 lakh, largely due to the absence of one-time receipts such as refund of delay supply charges (₹114.17 lakh) recognized in the prior year. This was partially offset by unclaimed creditors written back (₹30.74 lakh).

Balance Sheet and Debt

The company strengthened its balance sheet by fully repaying long-term borrowings of ₹173.58 lakh outstanding at the beginning of the year. As of March 31, 2026, Beryl Drugs had no long-term debt. Short-term borrowings stood at ₹239.13 lakh, primarily under a cash credit limit with Punjab National Bank.

Total assets decreased to ₹1,496.33 lakh from ₹1,598.69 lakh. Cash and cash equivalents fell to ₹27.35 lakh from ₹81.44 lakh. Trade receivables saw a sharp reduction to ₹208.83 lakh from ₹545.71 lakh, reflecting improved collection efforts. However, inventory levels rose to ₹312.64 lakh from ₹190.28 lakh, attributed to the accumulation of finished goods during the BFS shutdown.

Related-Party Transaction Approval

Beryl Drugs is seeking shareholder approval at its 33rd Annual General Meeting (AGM) on September 29, 2026, to increase the aggregate monetary limit for material related-party transactions with Aminova Infusions Pvt. Ltd. The proposed revision raises the ceiling from ₹5.00 crore to ₹8.00 crore.

Aminova Infusions is promoted by Mr. Shailendra Pathak, the Whole-Time Director of Beryl Drugs. The transactions involve the sale and distribution of PP bottles and FFS products. The Audit Committee recommended the proposal, citing Aminova’s market-development capabilities. No related party will vote on this resolution.

What the Numbers Show

The divergence between falling revenue and rising inventory highlights the operational disruption caused by the BFS shutdown. While trade receivables improved significantly—reducing working capital blockage—the reliance on short-term borrowings (₹239.13 lakh) against low cash reserves (₹27.35 lakh) indicates tight liquidity management during the recovery phase. The absence of long-term debt improves the capital structure, but profitability remains pressured until full production normalization is sustained.